Scarica l'app Stockscreener
17.76
0.40%
0.07
Pre-mercato:
18.20
0.44
+2.48%
Precedente Chiudi:
$17.69
Aprire:
$18.3
Volume 24 ore:
2.38M
Relative Volume:
2.90
Capitalizzazione di mercato:
$1.75B
Reddito:
-
Utile/perdita netta:
$-168.10M
Rapporto P/E:
-9.0043
EPS:
-1.9724
Flusso di cassa netto:
$-113.89M
1 W Prestazione:
+0.79%
1M Prestazione:
+4.29%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$17.50
$18.56
Intervallo di 1 settimana:
$16.55
$18.56
Portata 52W:
$14.62
$18.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Nome
Definium Therapeutics Inc
Settore
Industria
Telefono
212-220-6633
Indirizzo
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
17.76 | 1.74B | 0 | -168.10M | -113.89M | -1.9724 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Iniziato | Jefferies | Buy |
| 2025-10-13 | Iniziato | Needham | Buy |
| 2025-08-04 | Ripresa | Oppenheimer | Outperform |
| 2025-01-28 | Iniziato | Evercore ISI | Outperform |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-07-24 | Iniziato | ROTH MKM | Buy |
| 2024-05-29 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | Canaccord Genuity | Buy |
| 2022-12-09 | Ripresa | ROTH Capital | Buy |
| 2022-11-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-26 | Iniziato | Oppenheimer | Outperform |
| 2022-08-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Iniziato | ROTH Capital | Buy |
| 2021-06-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Definium Therapeutics Inc Borsa (DFTX) Ultime notizie
Number of shareholders of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Definium Therapeutics Inc: DT120's robust efficacy and rapid adoption potential position it as a transformative psychiatric therapy - TradingView
Definium Therapeutics Inc: DT120 demonstrated unprecedented efficacy in GAD and MDD, with broad adoption anticipated - TradingView
DFTX: HC Wainwright & Co. Raises Price Target to $70 | DFTX Stoc - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks - Yahoo Finance
DFTX Technical Analysis & Stock Price Forecast - Intellectia AI
Definium Therapeutics Advances DT120 ODT As Trials And Valuation Gain Focus - Sahm
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - Newswire Canada
Is Rising 2025 Loss and Investor Outreach Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
DFTX Should I Buy - Intellectia AI
Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Highlights: Strong Financial Position Amid Rising R&D Costs - GuruFocus
Decoding Definium Therapeutics Inc (DFTX): A Strategic SWOT Insi - GuruFocus
Definium Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Definium Therapeutics Q4 2025 reports strong R&D investment By Investing.com - Investing.com South Africa
Definium Therapeutics (NASDAQ:DFTX) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Definium Therapeutics Issues Inducement Stock Options to New Hires - TipRanks
Definium Therapeutics Inc: Four pivotal phase III studies near completion, with strong cash reserves and key data readouts ahead - TradingView
Definium Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Definium (DFTX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Definium Therapeutics posts full-year 2025 financial results, releases business update - Traders Union
Definium Therapeutics (DFTX) maps late-stage trials in anxiety, depression and autism - Stock Titan
[8-K] Definium Therapeutics, Inc. Reports Material Event | DFTX SEC FilingForm 8-K - Stock Titan
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates - Business Wire
Definium Therapeutics (DFTX) Stock Analysis Report | Financials & Insights - Benzinga España
Definium Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Definium Therapeutics (NASDAQ:DFTX) Research Coverage Started at Wolfe Research - Defense World
Earnings Preview For Definium Therapeutics - Benzinga
Definium Therapeutics (NASDAQ:DFTX) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
Biotech Firm Developing LSD-Based Psychiatric Treatments Moves to Dismiss Trade Secrets Lawsuit, Calls Claims by Former Clinical Trial Vendor Legally Deficient - USA Herald
DFTX: Wolfe Research Initiates Coverage with Outperform Rating | - GuruFocus
Definium Therapeutics to Participate at Upcoming Investor Conferences - The Globe and Mail
Definium Therapeutics (DFTX) to Release Quarterly Earnings on Thursday - MarketBeat
Jefferies assigns 65–75% probability of best-in-class efficacy for Definium Therapeutics, Inc.’s (DFTX) DT120 in Phase III - MSN
Avoro Capital Advisors LLC Acquires 5 Million Shares in Definium Therapeutics Inc - GuruFocus
CenterBook Partners LP Takes Position in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 - The Joplin Globe
Jefferies’ DT120 Confidence and Psychedelic Tailwinds Might Change The Case For Investing In Definium Therapeutics (DFTX) - Sahm
Jefferies Assigns 65-75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III - Bitget
Jefferies Assigns 65–75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.’s (DFTX) DT120 in Phase III - Insider Monkey
Definium Therapeutics (NASDAQ:DFTX) Stock Price Up 8.3%Still a Buy? - MarketBeat
Should I buy Definium Therapeutics, Inc. (DFTX) - Zacks Investment Research
Commodore Capital reports 7.2% Definium Therapeutics (DFTX) ownership stake - Stock Titan
7 Most Promising Psychedelic Stocks According to Hedge Funds - Insider Monkey
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation After Roger Adsett Joins The Board - Sahm
What is the current Price Target and Forecast for Definium Therapeutics, Inc. (DFTX) - Zacks Investment Research
Is Adsett’s Board Appointment And Breakthrough DT120 Status Altering The Investment Case For Definium Therapeutics (DFTX)? - simplywall.st
Pharma Co. Stole Secrets For LSD Medical Trials, Suit Says - Law360
Definium Therapeutics Inc Azioni (DFTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):